{
  "id": 4848946,
  "title": "Concerted changes in the pediatric single-cell intestinal ecosystem before and after anti-TNF blockade",
  "url": "https://urgent.news/2026/09/01/concerted-changes-in-the-pediatric-single-cell-intestinal-ecosystem",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T00:00:00.000Z",
  "source": {
    "name": "eLife",
    "slug": "elife",
    "url": "https://elifesciences.org/articles/91792"
  },
  "original_language": "en",
  "account": "Crohn's disease, an inflammatory bowel disorder, is often managed through anti-TNF blockade treatment. Despite this approach, many patients still experience relapse and disease progression. A recent study utilized comprehensive single-cell RNA-sequencing (scRNA-seq) atlases to examine pediatric patients with Crohn's disease (pediCD), comparing them to repeat biopsies after treatment and healthy controls with functional gastrointestinal disorders (FGIDs). By analyzing 201,883 baseline single-cell transcriptomes, researchers employed a principled and unbiased clustering method, ARBOL, to distinguish cell types and states in pediCD, FGID, and treatment-naive states. The findings revealed that treatment-naive pediatric CD and FGID share similar broad cell type composition, but treatment-naive pediCD exhibits significant differences in cell subsets and states compared to FGID. Through the integration of scRNA-seq analysis with clinical metadata, the study identified a vector of T cell, innate lymphocyte, myeloid, and epithelial cell states in pediCD-TIME samples, which can predict disease severity and response to anti-TNF treatment. By comparing on-treatment biopsies from pediatric patients with those from adult Crohn's disease patients, researchers found that anti-TNF treatment pushes the pediatric cellular ecosystem towards an adult, more treatment-refractory state. The study concludes that understanding baseline cell states in pediatric CD patients can help predict disease trajectories.",
  "summary": "Crohn’s disease is an inflammatory bowel disease (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled patients with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, and states at diagnosis anticipate disease…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}